Emily S. Lebow
YOU?
Author Swipe
View article: Periventricular radionecrosis after conventionally fractionated radiation for low grade meningiomas
Periventricular radionecrosis after conventionally fractionated radiation for low grade meningiomas Open
Background Radionecrosis (RN) is a serious late complication of radiotherapy (RT). While its risk is well characterized after stereotactic radiosurgery, RT dose thresholds for development of RN following conventionally fractionated RT (CFR…
View article: IMMU-49. Outcomes of SRS and Ipilimumab/Nivolumab Among Patients with Melanoma Brain Metastases
IMMU-49. Outcomes of SRS and Ipilimumab/Nivolumab Among Patients with Melanoma Brain Metastases Open
While ipilimumab and nivolumab has demonstrated promising intracranial activity among patients with melanoma brain metastases (BM), patients with prior systemic therapy exposure may be at higher risk of poor intracranial disease control an…
View article: Radiomic phenotypes of oligometastatic non-small cell lung cancer
Radiomic phenotypes of oligometastatic non-small cell lung cancer Open
This study identifies radiomic features of indolent NSCLC, demonstrating that flatter, higher surface area primary disease is associated with a greater number of metastases, and primary lesions with lower density representing lung parenchy…
View article: RDTA-13 OUTCOMES AFTER SRS AND IPILIMUMAB/NIVOLUMAB FOR PATIENTS WITH MELANOMA BRAIN METASTASES WITH OR WITHOUT PRIOR CHECKPOINT EXPOSURE
RDTA-13 OUTCOMES AFTER SRS AND IPILIMUMAB/NIVOLUMAB FOR PATIENTS WITH MELANOMA BRAIN METASTASES WITH OR WITHOUT PRIOR CHECKPOINT EXPOSURE Open
While ipilimumab/nivolumab has demonstrated promising intracranial activity among patients with melanoma brain metastases (BM), patients with prior immune checkpoint inhibition (ICI) exposure may be at higher risk of worse intracranial dis…
View article: Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy
Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy Open
In this retrospective study, clinically significant BM was most prevalent in those exposed to IO and not seen in those receiving chemotherapy despite similar mOS between the groups. Brain imaging should be considered before starting IO in …
View article: Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy Open
To the best of our knowledge, this is the first clinical report of outcomes using the guideline-recommended approach of local therapy for isolated brain relapse among patients receiving ADCs. Local therapy may delay the need for next line …
View article: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer Open
There is a need to identify predictive biomarkers to guide treatment strategies in stage III non-small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III NSCLC treated with concurrent chemoradiatio…
View article: Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases
Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases Open
This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic radiation necrosis.
View article: ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy Open
Background Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally adva…
View article: Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC Open
Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly charac…
View article: Bright Solar Futures
Bright Solar Futures Open
The Bright Solar Futures (BSF) program addresses national climate and energy concerns by fulfilling the need for more solar technicians. About to enter its 5th year, the program demonstrates how the need for alternative energy can be addre…
View article: Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab Open
Importance The addition of consolidative durvalumab to chemoradiation has improved disease control and survival in locally advanced non–small cell lung cancer (NSCLC). However, there remains a need to identify biomarkers for response to th…
View article: AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy Open
BACKGROUND: Little is known about the effectiveness of hypofractionated radiation therapy (HFRT) or stereotactic body radiation therapy (SBRT) for the treatment of patients with oligometastatic (OM) or oligoprogressive (OP) thymic malignan…
View article: Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers
Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers Open
Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly charac…
View article: BIOM-01. GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES
BIOM-01. GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES Open
PURPOSE Brain metastases (BM) are common in patients with anaplastic lymphoma kinase fusion-positive NSCLC (ALK+ NSCLC). We characterized the genomics of patients with ALK+ NSCLC BM treated with alectinib with or without local therapy to i…
View article: Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer
Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer Open
Total tumor volume greater than 65 mL was associated with cfDNA mutation detection in patients with advanced NSCLC.
View article: Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS Open
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA to Examine Somatic Sta…
View article: Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay Open
Circulating cell-free DNA (cfDNA) from blood plasma of cancer patients can be used to interrogate somatic tumor alterations non-invasively or when adequate tissue is unavailable. We have developed and clinically implemented MSK-ACCESS (Ana…
View article: Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay Open
Circulating cell-free DNA (cfDNA) from blood plasma of cancer patients can be used to interrogate somatic tumor alterations non-invasively or when adequate tissue is unavailable. We have developed and clinically implemented MSK-ACCESS (Ana…
View article: Seeking Consensus on the Terminology of Value-Based Transformation Through use of a Delphi Process
Seeking Consensus on the Terminology of Value-Based Transformation Through use of a Delphi Process Open
Collaboration among diverse stakeholders involved in the value transformation of health care requires consistent use of terminology. The objective of this study was to reach consensus definitions for the terms value-based care, value-based…
View article: Immunotherapy and Stereotactic Radiosurgery for Management of Patients With Lung Cancer Brain Metastases
Immunotherapy and Stereotactic Radiosurgery for Management of Patients With Lung Cancer Brain Metastases Open
Purpose: Despite the emerging role of PD-1 pathway inhibitors for patients with\nadvanced lung cancer, there is a paucity of data on the activity of these agents among patients with brain metastases. We investigated the outcomes of PD-1 pa…